ClinicalTrials.gg
Drug

AP 1903 reagent clinical trials

Also written AP1903 and Rimiducid.

studies test it
12
open now
2
in phase 3
0
first study started
2009

How each study uses AP 1903 reagent is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the AP 1903 reagent studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

AP1903
8

Other names

Rimiducid
4

Studies by the year they started

12 studies that test it; most in 2013 (2)

Studies that test AP 1903 reagent, by start year
YearStudies
20091
20111
20132
20142
20151
20161
20181
20191
20231
20261

By phase

A phase 1/2 study counts in both.

Phase 1
12
Phase 2
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 6 · Other 6

Bellicum Pharmaceuticals (5) · M.D. Anderson Cancer Center (2) · Baylor College of Medicine (1) · UNC Lineberger Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Beijing Biotech (1)

Often tested with

Tested in the same studies.

Rivogenlecleucel (3) · Fludarabine (2) · Cyclophosphamide (2) · Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201 (1) · Fludarabine phosphate (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test AP 1903 reagent.

Studies

Open first, then newest update. How each study uses AP 1903 reagent is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 12

Given beside what is tested · 23 — AP 1903 reagent is usual care or a partner of the new treatment

Showing 20 of 23.

Codes

What other systems call AP 1903 reagent · ClinicalTrials.gg INT004331

  • MeSH (NLM) C423866AP 1903 reagentConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) H564L1W5J2RIMIDUCIDConfirmed FDA, NLM

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.